Dualitas provides a high‑throughput DualScreen™ Bispecific Discovery Engine that functionally screens over 100,000 bispecific antibody combinations across the entire cell‑surface proteome. By identifying synergistic co‑target pairs and cell‑surface proximity mechanisms, the platform generates bispecific candidates with greater potency, higher maximal efficacy, and immune modulation beyond conventional inhibitors for autoimmune, allergic, and other inflammatory diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional bispecific antibody (BsAb) discovery relies on narrow, pre‑selected target pairs and limited screening capacity, which restricts the identification of synergistic co‑target combinations and novel cell‑surface proximity mechanisms. This results in therapeutics that often provide only additive effects and miss opportunities for enhanced potency and efficacy in immune‑mediated diseases.
Solution
Dualitas has built the DualScreen™ Bispecific Discovery Engine, a high‑throughput functional platform that screens the entire cell surfaceome to evaluate up to 100,000+ unique bispecific combinations. By testing these combinations in functional assays, DualScreen uncovers previously unexplored co‑target pairs that exhibit true synergistic activity rather than simple additivity. The engine rapidly generates bispecific antibody candidates with differentiated pharmacology, including greater potency, higher maximal efficacy (Emax), and immune modulation that can operate independently of ligand competition. Candidates discovered through DualScreen, such as DTX‑102 and DTX‑103, demonstrate preclinical profiles that surpass existing therapies in autoimmune, allergic, and other inflammatory indications.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to discover or co‑develop next‑generation bispecific antibodies for immune‑mediated and inflammatory disease programs.
Features
- Combinatorial screening of >100,000 bispecific antibody pairs across the full cell‑surface proteome
- Functional high‑throughput assays that identify synergistic co‑target mechanisms and cell‑surface proximity biology
- Generation of BsAbs that are inert as monospecific antibodies but become highly active when engaged with specific cell types
- Candidates exhibit increased potency, enhanced Emax, rapid onset of action, and immune modulation beyond conventional inhibitors
- Platform enables rapid de‑risking and lead optimization for therapeutic programs in autoimmune, allergic, and broader immune‑inflammatory diseases